R-Tech Ueno: Basic Agreement on the Licensing of Data of Recombinant Human Serum Albumin

October 19, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573) and the Chemo-Sero-Therapeutic Research Institute (hereinafter referred to as Kaketsuken) reached basic agreement today on the licensing of data of recombinant human serum albumin as described below:

Twitter
LinkedIn
Facebook
Email
Print

Alliances Asia